Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
EVH Transcript
Evolent Health, Inc. (EVH) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-11
Evolent Health, Inc. (EVH) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call presented strong financial performance with revenue and EBITDA at the upper range of guidance, driven by new launches and AI initiatives. The Q&A revealed confidence in future growth, with new contracts and stable oncology trends. Despite some uncertainty in membership impact on 2026 EBITDA, the overall sentiment remains positive with a focus on margin maturation and strategic partnerships. Considering the company's market cap of approximately $2.3 billion, the stock price is likely to react positively (2% to 8%) over the next two weeks.
Evolent Health, Inc. (EVH) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed picture: strong Adjusted EBITDA and a new partnership with Aetna are positive, but revenue misses guidance and cash flow challenges persist. The Q&A reveals cautious optimism but highlights delays and uncertainties, particularly with the Aetna contract and exchange trends. The market cap indicates moderate sensitivity to these factors, suggesting a neutral stock reaction.
Evolent Health, Inc. (EVH) Q1 2025 Earnings Call Transcript
Unknown5-9
The earnings call presented mixed signals: strong Q1 revenue but weak guidance, with no share buyback program announced. The Q&A revealed uncertainties in oncology trends and tariff impacts. Despite a positive cash flow outlook, competitive pressures and regulatory risks persist. Given the company's modest market cap, the stock is likely to remain stable, resulting in a neutral prediction.
EVH Slides
EVH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
